Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Rhea-AI Summary

Abeona Therapeutics (Nasdaq: ABEO) appointed James A. Gow, MD, MBA, MS, MHCM as Senior Vice President, Head of Clinical Development & Medical Affairs, effective October 20, 2025.

Dr. Gow brings >20 years of industry experience in gene therapy and ophthalmology, having led programs from Phase 1 through post-marketing and contributed to FDA approvals for therapies including Xibrom, Bromday, Prolensa, Bepreve and global approvals for Xiidra. He previously held executive roles at Shire, Takeda, Novartis, Biogen and SparingVision and holds medical and multiple graduate degrees from the University of Manitoba, Cornell and Harvard.

Positive

• 20+ years of clinical development and medical affairs experience
• Led programs from Phase 1 through post-marketing
• Track record tied to FDA approvals for multiple ophthalmic drugs
• Appointment effective immediately, adding executive clinical leadership

Negative

• No financial guidance or quantified commercial impact provided in the announcement

CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately.

"We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri, Chief Executive Officer of Abeona. "James has a proven track record of leading novel gene therapy programs for inherited retinal diseases. His addition to our team will be invaluable as we advance our pipeline and deliver transformative treatments to patients."

Dr. Gow has over 20 years of industry experience in clinical development and medical affairs and is a recognized expert in gene therapy, especially in ophthalmology. His track record in clinical development includes leading programs from Phase 1 through post-marketing studies, which led to the FDA approvals of Xibrom, Bromday, Prolensa, Bepreve and global regulatory approvals of Xiidra. Prior to Abeona, Dr. Gow has held executive leadership roles at several pharmaceutical and biotechnology companies, including Shire, Takeda, Novartis, Biogen and SparingVision. Dr. Gow earned his MD from the University of Manitoba, an MBA from Cornell University, a Master of Science in Healthcare Policy and Research from Cornell University, and a Master in Health Care Management from Harvard University.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN^® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN^®, Abeona Assist^TM, Abeona Therapeutics^®, and their related logos are trademarks of Abeona Therapeutics Inc.

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to commercialize ZEVASKYN; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Contacts:

Investor and Media
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com

Investor
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com

FAQ

Who is James A. Gow and what role did he take at Abeona (ABEO) on October 20, 2025?

James A. Gow was appointed Senior Vice President, Head of Clinical Development & Medical Affairs at Abeona effective October 20, 2025.

What clinical experience does Dr. Gow bring to Abeona (ABEO)?

Dr. Gow has over 20 years of industry experience and has led gene therapy and ophthalmology programs from Phase 1 through post-marketing studies.

Which approved drugs are linked to Dr. Gow’s prior clinical leadership before joining Abeona (ABEO)?

His track record includes roles tied to FDA approvals for Xibrom, Bromday, Prolensa, Bepreve and global approvals for Xiidra.

Which companies did Dr. Gow work at before joining Abeona (ABEO)?

He previously held executive leadership roles at Shire, Takeda, Novartis, Biogen and SparingVision.

What is the expected timing for Dr. Gow’s contributions to Abeona’s pipeline (ABEO)?

Dr. Gow’s appointment is effective immediately, positioning him to support ongoing clinical development and medical affairs work.

Did Abeona (ABEO) provide financial or guidance details tied to Dr. Gow’s hire?

No; the announcement does not include any financial guidance, expected costs, or quantified commercial impact tied to the hire.